Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors

被引：4

作者：

Aghel, Nazanin ^{[1
,2
]}

Vila, Rocio C. Baro C. ^{[2
,3
]}

Lui, Michelle ^{[4
]}

Hillis, Christopher ^{[5
]}

Leong, Darryl P. P. ^{[1
,2
]}

机构：

[1] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada

[2] McMaster Univ, Hamilton, ON, Canada

[3] Inst Cardiovasc Buenos Aires ICBA, Div Cardiol, Buenos Aires, Argentina

[4] Hamilton Hlth Sci, Hamilton, ON, Canada

[5] McMaster Univ, Dept Oncol, Hamilton, ON, Canada

来源：

CURRENT CARDIOLOGY REPORTS | 2023年 / 25卷 / 9期

关键词：

Bruton's tyrosine kinase inhibitor; Atrial fibrillation; Cardio-Oncology; B-cell malignancies; Ibrutinib; Heart failure; CHRONIC LYMPHOCYTIC-LEUKEMIA; CARDIOLOGY/AMERICAN HEART ASSOCIATION; MANTLE-CELL LYMPHOMA; TERM-FOLLOW-UP; ATRIAL-FIBRILLATION; IBRUTINIB USE; AMERICAN-COLLEGE; TREATMENT-NAIVE; TARGETING BTK; RISK;

D O I：

10.1007/s11886-023-01916-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose of ReviewBruton's tyrosine kinase inhibitors (BTKis) have changed the treatment and prognosis of several B-cell malignancies. However, since the approval of the first BTKi, ibrutinib, reports of cardiovascular adverse events especially atrial fibrillation have arisen. In this review, we discuss the cardiovascular side effects of BTKis and the management of these toxicities in clinical practice.Recent FindingsBTKIs increase the risks of atrial fibrillation, bleeding, hypertension, heart failure, and potentially ventricular arrhythmia. Newer second and third-generation BTKis appear to have a lower risk of cardiovascular adverse events; however, long-term follow-up data are not available for these new BTKis.BTKis are an effective treatment for some B-cell malignancies; however, they can cause cardiovascular side effects. The best preventive strategies to minimize cardiovascular complications remain undefined. Currently, a practical approach for managing patients receiving BTKis includes the management of cardiovascular risk factors and side effects of BTKis to prevent interruption of cancer treatment.

引用

页码：941 / 958

页数：18

共 76 条

[41] Ventricular arrhythmias and sudden death in patients taking ibrutinib [J].

Lampson, Benjamin L. ;

Yu, Lijian ;

Glynn, Robert J. ;

Barrientos, Jacqueline C. ;

Jacobsen, Eric D. ;

Banerji, Versha ;

Jones, Jeffrey A. ;

Walewska, Renata ;

Savage, Kerry J. ;

Michaud, Gregory F. ;

Moslehi, Javid J. ;

Brown, Jennifer R. .

BLOOD, 2017, 129 (18) :2581-2584

[42] Use of the CHA2DS2-VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation [J].

Lane, Deirdre A. ;

Lip, Gregory Y. H. .

CIRCULATION, 2012, 126 (07) :860-865

[43] The CLL12 trial: ibrutinib vs placebo in treatment-naive, early-stage chronic lymphocytic leukemia [J].

Langerbeins, Petra ;

Zhang, Can ;

Robrecht, Sandra ;

Cramer, Paula ;

Fuerstenau, Moritz ;

Al-Sawaf, Othman ;

von Tresckow, Julia ;

Fink, Anna-Maria ;

Kreuzer, Karl-Anton ;

Vehling-Kaiser, Ursula ;

Tausch, Eugen ;

Mueller, Lothar ;

Eckart, Michael Josef ;

Schlag, Rudolf ;

Freier, Werner ;

Gaska, Tobias ;

Balser, Christina ;

Reiser, Marcel ;

Stauch, Martina ;

Wendtner, Clemens-Martin ;

Fischer, Kirsten ;

Stilgenbauer, Stephan ;

Eichhorst, Barbara ;

Hallek, Michael .

BLOOD, 2022, 139 (02) :177-187

[44] 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [J].

Lawton, Jennifer S. ;

Tamis-Holland, Jacqueline E. ;

Bangalore, Sripal ;

Bates, Eric R. ;

Beckie, Theresa M. ;

Bischoff, James M. ;

Bittl, John A. ;

Cohen, Mauricio G. ;

DiMaio, J. Michael ;

Don, Creighton W. ;

Fremes, Stephen E. ;

Gaudino, Mario F. ;

Goldberger, Zachary D. ;

Grant, Michael C. ;

Jaswal, Jang B. ;

Kurlansky, Paul A. ;

Mehran, Roxana ;

Metkus, Thomas S. Jr Jr ;

Nnacheta, Lorraine C. ;

Rao, Sunil, V ;

Sellke, Frank W. ;

Sharma, Garima ;

Yong, Celina M. ;

Zwischenberger, Brittany A. .

CIRCULATION, 2022, 145 (03) :E18-E114

[45] Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies JACC: CardioOncology State-of-the-Art Review [J].

Leong, Darryl P. ;

Cirne, Filipe ;

Aghel, Nazanin ;

Vila, Rocio C. Baro ;

Cavalli, Germano D. ;

Ellis, Peter M. ;

Healey, Jeff S. ;

Whitlock, Richard ;

Khalaf, Dina ;

Mian, Hira ;

Jolly, Sanjit S. ;

Mehta, Shamir R. ;

Dent, Susan .

JACC: CARDIOONCOLOGY, 2023, 5 (04) :415-430

[46] The European Society of Cardiology Cardio-Oncology Guidelines Evidence Base, Actionability, and Relevance to Clinical Practice [J].

Leong, Darryl P. ;

Mukherjee, Som D. .

JACC: CARDIOONCOLOGY, 2023, 5 (01) :137-140

[47] The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis [J].

Leong, Darryl P. ;

Caron, Francois ;

Hillis, Christopher ;

Duan, Annie ;

Healey, Jeff S. ;

Fraser, Graeme ;

Siegal, Deborah .

BLOOD, 2016, 128 (01) :138-140

[48]

Mato AR, 2021, LANCET, V397, P892, DOI 10.1016/S0140-6736(21)00224-5

[49]

Mendez-Ruiz Alan, 2023, J Soc Cardiovasc Angiogr Interv, V2, P100608, DOI 10.1016/j.jscai.2023.100608

[50] Risk of Major Bleeding with Ibrutinib [J].

Mock, Joseph ;

Kunk, Paul R. ;

Palkimas, Surabhi ;

Sen, Jeremy M. ;

Devitt, Michael ;

Horton, Bethany ;

Portell, Craig A. ;

Williams, Michael E. ;

Maitland, Hillary .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (11) :755-761

← 1 2 3 4 5 6 7 8 →